Literature DB >> 16386273

Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease.

Louis H Weimer1, David Podwall.   

Abstract

Toxin or medication-induced worsening of preexisting peripheral neuropathy is a generally accepted but not well-studied phenomenon in humans. Drug-induced exacerbation of Charcot Marie Tooth disease (CMT) neuropathy is a common concern; a list of potential drugs to avoid is maintained by the CMT Association but with limited direct evidence or advice on relative risk. An extensive literature search for reported cases of drug effects in CMT patients found the vast majority concerned excessive vincristine toxicity in patients with undiagnosed demyelinating forms of CMT, many after 1 or 2 doses. The CMT North American database was also queried for all drug-related effects. All but one drug cited as worsening neuropathy was present on a compiled inclusive list. These results and other available evidence were used to develop a revised risk stratified list for CMT patients and clinicians to consult prior to discussing risk to benefit ratios and making treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16386273     DOI: 10.1016/j.jns.2005.11.014

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  22 in total

1.  Exacerbation of Charcot-Marie-Tooth type 2E neuropathy following traumatic nerve injury.

Authors:  Eric Villalón; Jeffrey M Dale; Maria Jones; Hailian Shen; Michael L Garcia
Journal:  Brain Res       Date:  2015-09-28       Impact factor: 3.252

2.  Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.

Authors:  Tomonori Nakamura; Akihiro Hashiguchi; Shinsuke Suzuki; Kimiharu Uozumi; Shoko Tokunaga; Hiroshi Takashima
Journal:  Neurogenetics       Date:  2012-01-25       Impact factor: 2.660

3.  Expressing hNF-LE397K results in abnormal gaiting in a transgenic model of CMT2E.

Authors:  J M Dale; E Villalon; S G Shannon; D M Barry; R M Markey; V B Garcia; M L Garcia
Journal:  Genes Brain Behav       Date:  2012-02-23       Impact factor: 3.449

4.  Therapeutic strategies for the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 5.  A review of genetic counseling for Charcot Marie Tooth disease (CMT).

Authors:  Carly E Siskind; Seema Panchal; Corrine O Smith; Shawna M E Feely; Joline C Dalton; Alice B Schindler; Karen M Krajewski
Journal:  J Genet Couns       Date:  2013-04-21       Impact factor: 2.537

Review 6.  Mitochondrial fusion, fission, and mitochondrial toxicity.

Authors:  Joel N Meyer; Tess C Leuthner; Anthony L Luz
Journal:  Toxicology       Date:  2017-08-05       Impact factor: 4.221

7.  Treatment-induced remission of medulloblastoma using a chemotherapeutic regimen devoid of vincristine in a child with Charcot-Marie-Tooth disease.

Authors:  J D Bernstock; J L Cohen; S Singh; C W Schlappi; J B Fiveash; J M Johnston; P Fequiere; B A Orr; R Li; G K Friedman
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

8.  A novel system to accelerate the progression of nerve degeneration in transgenic mouse models of neuropathies.

Authors:  Osefame Ewaleifoh; Minh Trinh; John W Griffin; Thien Nguyen
Journal:  Exp Neurol       Date:  2012-06-09       Impact factor: 5.330

9.  Therapeutic implications of protein homeostasis in demyelinating peripheral neuropathies.

Authors:  Samuel M Lee; Lih-Shen Chin; Lian Li
Journal:  Expert Rev Neurother       Date:  2012-09       Impact factor: 4.618

10.  PMP22 expression in dermal nerve myelin from patients with CMT1A.

Authors:  Istvan Katona; Xingyao Wu; Shawna M E Feely; Stephanie Sottile; Carly E Siskind; Lindsey J Miller; Michael E Shy; Jun Li
Journal:  Brain       Date:  2009-05-15       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.